Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis to Use Invitrogen s Assays for Drug Discovery

NEW YORK, Aug 12 (GenomeWeb News) - Invitrogen said today that it will provide Exelixis with validated high-throughput screening assays for drug discovery in single live cells, which Exelixis will use for lead discovery and optimization.


Carlsbad, Calif.-based Invitrogen said that its Drug Discovery Solutions group would provide Exelixis with its GeneBlazer and Voltage Sensor Probe technologies for compound screening. The GeneBlazer cell-based beta-lactamase system combines molecular and cellular biology with a fluorescence resonance energy transfer-based detection method for high-throughput screening experiments.


Invitrogen recently announced that the GeneBlazer and Voltage Sensor Probe technologies would be available for purchase by researchers without a licensing agreement.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.